Company / Capital Returned to Shareholders
Alaunos Therapeutics, Inc. Capital Returned to Shareholders History
FY2012-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$45.0K
FY2023
5-year range
$0 / $45.0K
FY2019-FY2023
Trend
-
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Returned to Shareholders has fluctuated over the past 7 years, ranging from $0 in FY2022 to $2M in FY2012.
Based on SEC 10-K filings.
$45,000 in FY2023 with a 10-year CAGR of -16.5%.
Declined from $2M to $45,000 over the past 3 years.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -69.7%
- 5-Year CAGR
- +86.4%
- 10-Year CAGR
- -16.5%
Key checks
Key Insights
- 5-year CAGR of +86.4%, indicating consistent growth.
- Peak capital returned to shareholders was recorded in FY2012.
- Lowest capital returned to shareholders in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -3.79 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $45.0K | - |
| FY2022 | $0 | - |
| FY2021 | - | - |
| FY2020 | $1.6M | - |
| FY2019 | $0 | -100.0% |
| FY2018 | $2.0K | -99.3% |
| FY2013 | $274.0K | -83.6% |
| FY2012 | $1.7M | +338.9% |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026